Navigation Links
U.S. Patent Issued for Champions Biotechnology's Lead Oncology Drug
Date:10/13/2009

BALTIMORE, Oct. 13 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a drug development company with a preclinical platform able to predict clinical effectiveness, accelerate development and enhance the value of oncology drugs, today announced that the United States Patent and Trademark Office issued a patent on September 29, 2009 for the company's tubulin inhibitors, including its lead compound SG410. U.S. Patent No. 7,595,326 entitled "Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs" protects the Company's composition of matter, pharmaceutical composition, and method of treatment for SG410. The patent is owned by Champions Biotechnology.

"This patent solidifies Champions' intellectual property position on SG410. We believe that SG410, in the new Neowater formulation we developed, has the potential to significantly impact the treatment of cancer," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "SG410 is Champions' first internal compound and is currently undergoing Biomerk Tumorgraft(TM) evaluation. The results of SG410 tests in our predictive platform are expected to be available soon. We are also actively evaluating high potential compounds to build our oncology drug pipeline and expect to in-license additional drugs in the near future. Studies suggest that evaluations of compounds through Biomerk Tumorgrafts will lead to more successful and efficient clinical development."

For more information regarding Champions Biotechnology's growing business and recent news, please visit www.championsbiotechnology.com.

About SG410

SG410 is an antimitotic inhibitor that was shown in Tumorgraft models to target microtubule associated protein tau (MAPT) deficient tumors with promising results as compared to a currently marketed and leading chemotherapeutic drug. These antimitotic inhibitors target MAPT (Microtubule-Associated Protein Tau) deficient tumors. In both in vitro and in vivo models, SG410 has demonstrated promising activity against prostate and pancreatic cancer.

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

www.championsbiotechnology.com

www.personalizedcancertreatment.com

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2009 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.

For more news and information on Champions Biotechnology, Inc., please visit www.IRGnews.com/coi/CSBR where you can find the CEO's video, a fact sheet on the company, investor presentations, and more.

    CONTACT:
    The Investor Relations Group, Inc.
    James Carbonara
    +1-212-825-3210

SOURCE Champions Biotechnology, Inc.


'/>"/>
SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
3. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
4. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
5. United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food
6. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
7. United States Patent and Trademark Office Publishes Stemedicas Patent Application for the Treatment of Diabetic Retinopathy
8. MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
9. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
10. ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
11. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und ... Überlegenheit in ‚ausgezeichneter plus guter ... Colons    ,      (Logo: ... gab heute neue positive Daten von der MORA-Studie ...
(Date:5/24/2016)... 24, 2016  Diana Russell suffers from a form ... the inside out.  This disease has put her in ... children and grandchildren to leave her home.  Because of ... cannot haul the wheelchair.  So if there is a ... Diana is left to wait for the bus. ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... New studies published ... injured workers across 15 states. The outcomes examined in these studies include recovery ... care, and satisfaction with medical care. , “The goal of the studies is ...
(Date:5/25/2016)... , ... May 25, 2016 , ... CloudLIMS, joins an ... and Life Sciences Tech Solution Providers list of 2016 by CIOReview. , In a ... and Life Sciences Tech Solution Providers 2016 has been concluded with. The positioning is ...
(Date:5/25/2016)... ... May 25, 2016 , ... The World Molecular Imaging ... Molecular Imaging.” The focus of ADDMI-IG will be geared towards how using molecular ... issues. Through ADDMI-IG WMIS will provide a platform for productive discussions about the ...
(Date:5/25/2016)... ... 2016 , ... DKT International, one of the largest private ... to release their 2015 global impact data. In 2015, DKT served over 30 ... and 3.8 million unsafe abortions across 21 countries worldwide. , “We are ...
(Date:5/25/2016)... ... May 25, 2016 , ... Afrimesure specializes in ... and pharmaceutical, to food and HVAC facilities. Their knowledgeable staff also takes care ... For medical applications, Afrimesure offers a variety of MadgeTech systems available for sterilization ...
Breaking Medicine News(10 mins):